Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Clinical research trials and Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer. Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.

Home > "M" Clinical Trials Conditions > Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer



Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

For Condition: Cancer
Status: Recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have leptomeningeal cancer.
Details: OBJECTIVES: - Define the clinical toxicities of intrathecal iodine I 131 monoclonal antibody 3F8 (I-3F8) in patients with GD2 positive leptomeningeal neoplasms. - Determine whether I-3F8 can detect GD2 positive leptomeningeal tumors. - Measure the cerebrospinal fluid (CSF) levels and serum pharmacokinetics of I-3F8 in these patients. OUTLINE: This is a dose escalation study. Patients receive a single injection of intraventricular or intrathecal iodine I 131 monoclonal antibody 3F8. Patients without objective disease progression and no grade 3 or 4 toxicity 6 weeks after the first dose may receive a second injection. Cohorts of at least 3 patients are entered at escalating doses of I-3F8. If grade 3 or worse toxicity occurs in 1 or more of 3 patients at a given dose level, then 3 additional patients are accrued at that level. If 2 or more of 6 patients at a given dose level experience grade 3 or worse toxicity, then that dose is declared the maximum tolerated dose (MTD). Patients are followed weekly for 4 weeks. PROJECTED ACCRUAL: Approximately 3-30 patients will be accrued for this study over 2-3 years.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 3 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed malignancy expressing GD2, including, but not limited to: - Medulloblastoma/primitive neuroectodermal tumor of the CNS - Malignant glioma - Neuroblastoma - Retinoblastoma - Ependymoma - Sarcoma - Melanoma - Small cell lung carcinoma - Other tumor types must have GD2 expression confirmed by immunohistochemical staining - Cerebrospinal fluid or leptomeningeal disease that is refractory to conventional therapy or for which no conventional therapy exists - Prior measurable human anti-mouse monoclonal antibody titer allowed PATIENT CHARACTERISTICS: Age: - 3 and over Performance status: - Not specified Life expectancy: - At least 2 months Hematopoietic: - Absolute neutrophil count greater than 1,000/mm^3 - Platelet count greater than 50,000/mm^3 Hepatic: - Bilirubin less than 3 mg/dL Renal: - Creatinine less than 2 mg/dL - Blood urea nitrogen less than 30 mg/dL Other: - May have active malignancy outside the central nervous system - No obstructive hydrocephalus - No CNS grade 3 or 4 toxicity as a consequence of prior treatments - No life threatening infection PRIOR CONCURRENT THERAPY: Biologic therapy: - Prior monoclonal antibody treatment allowed Chemotherapy: - Prior chemotherapy allowed - Must have recovered from all hematopoietic and neurologic side effects of prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - Prior radiotherapy allowed - At least 6 weeks since prior cranial or spinal irradiation Surgery: - Not specified
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
KimKramer,  Study Chair,  Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City,  New York,  10021
United States
Recruiting Kim  Kramer 212-639-6410


Additional Information:
Study ID Numbers:  CDR0000065607;  MSKCC-97021,NCI-G97-1267
Study Start Date: 
Record last reviewed: November 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003022

Other Cancer Studies:
1. Promoting Healthy Lifestyles

2. Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

3. Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer or Other Solid Tumors

4. Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors

5. A Phase I Study of a Histone Deacetylase Inhibitor, MS-275, with an Oral 28-Day Dosing Schedule in Refractory Solid Tumors and Lymphomas

Related Studies:

Other Cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Modify your Search

  Other Cancer Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103